Generoath is moving into the future today.

Technology Overview
  • - First-in-class therapeutics with novel target
  • - Neurodegeneration-focused pipelines

Gene X coding AAV

  • GO-101 : Parkinson`s Disease(PD)
  • GO-102 : Amyotrophic Lateral Sclerosis (ALS)
  • GO-201 : Retinal Degenerative Disease(RDD)
  • Intracranial injection
  • Intrathecal injection
  • Subretinal/ Intravitreal injection
  • Recombinant self-complementary AAV
  • Safe profile
  • Engineered for expression only at injected site
MOA of GO drugs
  • - First-in-class medicine that with novel transgene
  • - Fundamental curative mechanism that suppresses neuronal cell apoptosis
  • - Stable and long term transgene expression in CNS: lifelong treatment following a single injection
Mode of Action

Our GO series transgene “Gene X”: a powerful and multi-faceted modulator of cell survival and death in neurodegenerative disease.

  • Gene A is multi-functional and potent cell death-inducing gene
  • Gene X is a splicing variant of Gene A.
  • Gene X acts as an antagonistic competitor against Gene A.
  • Gene X inhibits Gene A-induced cell death.